{
  "kind": "all",
  "value": "all",
  "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations",
  "filters": {
    "documentKinds": [],
    "sourceTypes": [],
    "orientations": []
  },
  "total": 319975,
  "page": 3692,
  "pageSize": 60,
  "pageCount": 5333,
  "rows": [
    {
      "docId": "019de076-4a3e-76ed-83f8-e348223f91d9",
      "docSlug": "c1eecdcf261eded4e99ffa840c30e475",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 44,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The slide uses a bar chart to compare two groups of drugs and their associated companies.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/44",
      "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9",
      "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-44",
      "loopMatches": [
        {
          "to": 60,
          "from": 3,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "50c25ad2-0c48-4213-947d-b362da490be1",
          "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative",
          "position": 1,
          "objective": "Why is Immix Biopharma's N-GENIUS platform important?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.7,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4a3e-76ed-83f8-e348223f91d9",
      "docSlug": "c1eecdcf261eded4e99ffa840c30e475",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 45,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Slide presents three distinct preclinical data sets: survival in STS mice, tumor response in STS mice, and survival in KPC pancreatic cancer mice.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/45",
      "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9",
      "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-45",
      "loopMatches": [
        {
          "to": 60,
          "from": 3,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "50c25ad2-0c48-4213-947d-b362da490be1",
          "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative",
          "position": 1,
          "objective": "Why is Immix Biopharma's N-GENIUS platform important?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.7,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4a3e-76ed-83f8-e348223f91d9",
      "docSlug": "c1eecdcf261eded4e99ffa840c30e475",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 46,
      "slideType": "other",
      "function": "illustrate_case",
      "notes": "Includes a process flow diagram illustrating the mechanism of action of IMX-110 in tumor microenvironments.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/46",
      "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9",
      "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-46",
      "loopMatches": [
        {
          "to": 60,
          "from": 3,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "50c25ad2-0c48-4213-947d-b362da490be1",
          "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative",
          "position": 1,
          "objective": "Why is Immix Biopharma's N-GENIUS platform important?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.7,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4a3e-76ed-83f8-e348223f91d9",
      "docSlug": "c1eecdcf261eded4e99ffa840c30e475",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 47,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes Kaplan-Meier survival curves and bioluminescence imaging of tumor activity.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/47",
      "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9",
      "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-47",
      "loopMatches": [
        {
          "to": 60,
          "from": 3,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "50c25ad2-0c48-4213-947d-b362da490be1",
          "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative",
          "position": 1,
          "objective": "Why is Immix Biopharma's N-GENIUS platform important?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.7,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4a3e-76ed-83f8-e348223f91d9",
      "docSlug": "c1eecdcf261eded4e99ffa840c30e475",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 48,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes waterfall and spider/line plots for patient response data.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/48",
      "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9",
      "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-48",
      "loopMatches": [
        {
          "to": 60,
          "from": 3,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "50c25ad2-0c48-4213-947d-b362da490be1",
          "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative",
          "position": 1,
          "objective": "Why is Immix Biopharma's N-GENIUS platform important?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.7,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4a3e-76ed-83f8-e348223f91d9",
      "docSlug": "c1eecdcf261eded4e99ffa840c30e475",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 49,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The slide uses a bubble chart to map clinical trials and a table to detail drug performance metrics.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/49",
      "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9",
      "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-49",
      "loopMatches": [
        {
          "to": 60,
          "from": 3,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "50c25ad2-0c48-4213-947d-b362da490be1",
          "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative",
          "position": 1,
          "objective": "Why is Immix Biopharma's N-GENIUS platform important?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.7,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4a3e-76ed-83f8-e348223f91d9",
      "docSlug": "c1eecdcf261eded4e99ffa840c30e475",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 50,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The slide uses a combination of a conceptual chart and a data table to demonstrate efficacy in heavily pre-treated patients.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/50",
      "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9",
      "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-50",
      "loopMatches": [
        {
          "to": 60,
          "from": 3,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "50c25ad2-0c48-4213-947d-b362da490be1",
          "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative",
          "position": 1,
          "objective": "Why is Immix Biopharma's N-GENIUS platform important?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.7,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4a3e-76ed-83f8-e348223f91d9",
      "docSlug": "c1eecdcf261eded4e99ffa840c30e475",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 51,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "The slide uses a process flow diagram to illustrate the clinical development path for two different treatment regimens.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/51",
      "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9",
      "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-51",
      "loopMatches": [
        {
          "to": 60,
          "from": 3,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "50c25ad2-0c48-4213-947d-b362da490be1",
          "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative",
          "position": 1,
          "objective": "Why is Immix Biopharma's N-GENIUS platform important?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.7,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4a3e-76ed-83f8-e348223f91d9",
      "docSlug": "c1eecdcf261eded4e99ffa840c30e475",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 52,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes a comparative diagram of the drug molecule vs standard IgG antibody and multiple clinical/preclinical data charts.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/52",
      "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9",
      "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-52",
      "loopMatches": [
        {
          "to": 60,
          "from": 3,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "50c25ad2-0c48-4213-947d-b362da490be1",
          "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative",
          "position": 1,
          "objective": "Why is Immix Biopharma's N-GENIUS platform important?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.7,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4a3e-76ed-83f8-e348223f91d9",
      "docSlug": "c1eecdcf261eded4e99ffa840c30e475",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 53,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes two sets of charts: tumor volume line graphs and survival curves for MDA-MB-231 and HCT-116 models.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/53",
      "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9",
      "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-53",
      "loopMatches": [
        {
          "to": 60,
          "from": 3,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "50c25ad2-0c48-4213-947d-b362da490be1",
          "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative",
          "position": 1,
          "objective": "Why is Immix Biopharma's N-GENIUS platform important?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.7,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4a3e-76ed-83f8-e348223f91d9",
      "docSlug": "c1eecdcf261eded4e99ffa840c30e475",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 54,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes detailed scientific diagrams of the drug mechanism and clinical trial results.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/54",
      "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9",
      "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-54",
      "loopMatches": [
        {
          "to": 60,
          "from": 3,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "50c25ad2-0c48-4213-947d-b362da490be1",
          "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative",
          "position": 1,
          "objective": "Why is Immix Biopharma's N-GENIUS platform important?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.7,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4a3e-76ed-83f8-e348223f91d9",
      "docSlug": "c1eecdcf261eded4e99ffa840c30e475",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 55,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses a bar chart comparison to highlight the efficacy gap between established treatments and placebo.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/55",
      "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9",
      "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-55",
      "loopMatches": [
        {
          "to": 60,
          "from": 3,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "50c25ad2-0c48-4213-947d-b362da490be1",
          "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative",
          "position": 1,
          "objective": "Why is Immix Biopharma's N-GENIUS platform important?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.7,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4a3e-76ed-83f8-e348223f91d9",
      "docSlug": "c1eecdcf261eded4e99ffa840c30e475",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 56,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a side-by-side comparison of two proprietary technology platforms.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/56",
      "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9",
      "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-56",
      "loopMatches": [
        {
          "to": 60,
          "from": 3,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "50c25ad2-0c48-4213-947d-b362da490be1",
          "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative",
          "position": 1,
          "objective": "Why is Immix Biopharma's N-GENIUS platform important?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.7,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4a3e-76ed-83f8-e348223f91d9",
      "docSlug": "c1eecdcf261eded4e99ffa840c30e475",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 57,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a process-flow style layout to connect platform capabilities to specific product outcomes.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/57",
      "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9",
      "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-57",
      "loopMatches": [
        {
          "to": 60,
          "from": 3,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "50c25ad2-0c48-4213-947d-b362da490be1",
          "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative",
          "position": 1,
          "objective": "Why is Immix Biopharma's N-GENIUS platform important?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.7,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4a3e-76ed-83f8-e348223f91d9",
      "docSlug": "c1eecdcf261eded4e99ffa840c30e475",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 58,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "The slide uses a serpentine process flow (1-5 left-to-right, 6-10 right-to-left).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/58",
      "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9",
      "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-58",
      "loopMatches": [
        {
          "to": 60,
          "from": 3,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "50c25ad2-0c48-4213-947d-b362da490be1",
          "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative",
          "position": 1,
          "objective": "Why is Immix Biopharma's N-GENIUS platform important?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.7,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4a3e-76ed-83f8-e348223f91d9",
      "docSlug": "c1eecdcf261eded4e99ffa840c30e475",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 59,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a process-like flow from the 3 pillars to the specific product outcomes.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/59",
      "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9",
      "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-59",
      "loopMatches": [
        {
          "to": 60,
          "from": 3,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "50c25ad2-0c48-4213-947d-b362da490be1",
          "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative",
          "position": 1,
          "objective": "Why is Immix Biopharma's N-GENIUS platform important?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.7,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4a3e-76ed-83f8-e348223f91d9",
      "docSlug": "c1eecdcf261eded4e99ffa840c30e475",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 60,
      "slideType": "cover",
      "function": "front_matter",
      "notes": "Includes date and ticker symbol.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/60",
      "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9",
      "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-60",
      "loopMatches": [
        {
          "to": 60,
          "from": 3,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "50c25ad2-0c48-4213-947d-b362da490be1",
          "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative",
          "position": 1,
          "objective": "Why is Immix Biopharma's N-GENIUS platform important?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.7,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 1,
      "slideType": "cover",
      "function": "front_matter",
      "notes": null,
      "imagePath": "https://imgproxy.kitesheet.com/6M1kLlDf6aUtjUIztbI9oMwJUQA8i0LFwlfx6acEkIA/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jMjQxYWM5ZWRkMjQ0MzQ1MjI1Nzk0OWNlMGE3M2Q2NS9wMDAxLmpwZw",
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/1",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-1",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 3,
          "from": 1,
          "beatId": "cfa0c1bd-b8ce-4ae0-b88d-4c0c279158ba",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Attention",
          "beatSlug": "aida-attention",
          "evidence": "The deck starts with a cover slide, disclaimer, and executive summary highlighting key points",
          "position": 0,
          "confidence": 0.8,
          "parentBeatName": "Hook",
          "parentBeatSlug": "hook"
        }
      ],
      "imagePathAlt": "https://imgproxy.kitesheet.com/4EGsxIdAySQwMOmgUj0a2ww7dNyFy3dgxu7a5daZOMc/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jMjQxYWM5ZWRkMjQ0MzQ1MjI1Nzk0OWNlMGE3M2Q2NS9wMDAxLnBuZw",
      "thumbSrc": "https://imgproxy.kitesheet.com/e-gmlWg0zwX2ff0wQrl4e8uJyP1ZRJ744CIeHk4WHI0/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jMjQxYWM5ZWRkMjQ0MzQ1MjI1Nzk0OWNlMGE3M2Q2NS9wMDAxLmpwZw",
      "thumbSrcAlt": "https://imgproxy.kitesheet.com/dc7QwUEwkzv8cwPeZLV2mMF6s1eQlV8uCxzTnFPAt7o/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jMjQxYWM5ZWRkMjQ0MzQ1MjI1Nzk0OWNlMGE3M2Q2NS9wMDAxLnBuZw"
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 2,
      "slideType": "disclaimer",
      "function": "other",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/2",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-2",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 3,
          "from": 1,
          "beatId": "cfa0c1bd-b8ce-4ae0-b88d-4c0c279158ba",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Attention",
          "beatSlug": "aida-attention",
          "evidence": "The deck starts with a cover slide, disclaimer, and executive summary highlighting key points",
          "position": 0,
          "confidence": 0.8,
          "parentBeatName": "Hook",
          "parentBeatSlug": "hook"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 3,
      "slideType": "executive_summary",
      "function": "summarize",
      "notes": "The slide uses a numbered list format to present key value propositions.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/3",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-3",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 3,
          "from": 1,
          "beatId": "cfa0c1bd-b8ce-4ae0-b88d-4c0c279158ba",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Attention",
          "beatSlug": "aida-attention",
          "evidence": "The deck starts with a cover slide, disclaimer, and executive summary highlighting key points",
          "position": 0,
          "confidence": 0.8,
          "parentBeatName": "Hook",
          "parentBeatSlug": "hook"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 4,
      "slideType": "team_bio",
      "function": "other",
      "notes": "The slide uses a grid-based layout to categorize team members into three distinct groups: Leadership, Board of Directors, and Scientific Advisory Board.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/4",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-4",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 9,
          "from": 4,
          "beatId": "7719616c-f553-44bf-8bfe-cc092ccfc183",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Interest",
          "beatSlug": "aida-interest",
          "evidence": "The team bio, solution overview, and N-GENIUS platform details generate interest",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 5,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a causal-chain framework to link platform capabilities to strategic outcomes.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/5",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-5",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 9,
          "from": 4,
          "beatId": "7719616c-f553-44bf-8bfe-cc092ccfc183",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Interest",
          "beatSlug": "aida-interest",
          "evidence": "The team bio, solution overview, and N-GENIUS platform details generate interest",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 6,
      "slideType": "pain_points",
      "function": "frame_problem",
      "notes": "Uses a hub-and-spoke diagram to illustrate the negative impacts of a central problem.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/6",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-6",
      "loopMatches": [
        {
          "to": 9,
          "from": 6,
          "name": "Logic Chain",
          "slug": "01-logic-chain",
          "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
          "matchId": "2a731b3e-52c5-46a2-b542-abdc9832fb4b",
          "evidence": "The deck logically connects the platform's components to its advantages",
          "position": 0,
          "objective": "Explain the N-GENIUS platform technology",
          "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
          "confidence": 0.8,
          "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 9,
          "from": 4,
          "beatId": "7719616c-f553-44bf-8bfe-cc092ccfc183",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Interest",
          "beatSlug": "aida-interest",
          "evidence": "The team bio, solution overview, and N-GENIUS platform details generate interest",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 7,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a structural diagram to highlight the substitution of the 'Tumor Binding Domain' with the 'COBRA Binder' in the NXC-201 molecule.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/7",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-7",
      "loopMatches": [
        {
          "to": 9,
          "from": 6,
          "name": "Logic Chain",
          "slug": "01-logic-chain",
          "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
          "matchId": "2a731b3e-52c5-46a2-b542-abdc9832fb4b",
          "evidence": "The deck logically connects the platform's components to its advantages",
          "position": 0,
          "objective": "Explain the N-GENIUS platform technology",
          "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
          "confidence": 0.8,
          "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 9,
          "from": 4,
          "beatId": "7719616c-f553-44bf-8bfe-cc092ccfc183",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Interest",
          "beatSlug": "aida-interest",
          "evidence": "The team bio, solution overview, and N-GENIUS platform details generate interest",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 8,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a schematic diagram to map specific protein domains to their functional benefits.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/8",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-8",
      "loopMatches": [
        {
          "to": 9,
          "from": 6,
          "name": "Logic Chain",
          "slug": "01-logic-chain",
          "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
          "matchId": "2a731b3e-52c5-46a2-b542-abdc9832fb4b",
          "evidence": "The deck logically connects the platform's components to its advantages",
          "position": 0,
          "objective": "Explain the N-GENIUS platform technology",
          "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
          "confidence": 0.8,
          "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 9,
          "from": 4,
          "beatId": "7719616c-f553-44bf-8bfe-cc092ccfc183",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Interest",
          "beatSlug": "aida-interest",
          "evidence": "The team bio, solution overview, and N-GENIUS platform details generate interest",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 9,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses academic citations to validate the mechanism of action for their CAR-T design.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/9",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-9",
      "loopMatches": [
        {
          "to": 9,
          "from": 6,
          "name": "Logic Chain",
          "slug": "01-logic-chain",
          "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
          "matchId": "2a731b3e-52c5-46a2-b542-abdc9832fb4b",
          "evidence": "The deck logically connects the platform's components to its advantages",
          "position": 0,
          "objective": "Explain the N-GENIUS platform technology",
          "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
          "confidence": 0.8,
          "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 9,
          "from": 4,
          "beatId": "7719616c-f553-44bf-8bfe-cc092ccfc183",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Interest",
          "beatSlug": "aida-interest",
          "evidence": "The team bio, solution overview, and N-GENIUS platform details generate interest",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 10,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the superiority of NXC-201.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/10",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-10",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 10,
          "beatId": "7f3ecbba-6032-4531-bb7e-529e9174ab66",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Desire",
          "beatSlug": "aida-desire",
          "evidence": "The competitive analysis, solution advantages, and clinical data create desire for the technology",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 11,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide compares HSL (Heavy-chain-led) vs LSH (Light-chain-led) configurations using bar charts for expansion and cytotoxicity metrics.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/11",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-11",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 10,
          "beatId": "7f3ecbba-6032-4531-bb7e-529e9174ab66",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Desire",
          "beatSlug": "aida-desire",
          "evidence": "The competitive analysis, solution advantages, and clinical data create desire for the technology",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 12,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes a cartoon character graphic at the bottom.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/12",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-12",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 10,
          "beatId": "7f3ecbba-6032-4531-bb7e-529e9174ab66",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Desire",
          "beatSlug": "aida-desire",
          "evidence": "The competitive analysis, solution advantages, and clinical data create desire for the technology",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 13,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses a bar chart combined with a data table to highlight safety advantages. It includes a disclaimer about cross-trial comparisons.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/13",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-13",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 10,
          "beatId": "7f3ecbba-6032-4531-bb7e-529e9174ab66",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Desire",
          "beatSlug": "aida-desire",
          "evidence": "The competitive analysis, solution advantages, and clinical data create desire for the technology",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 14,
      "slideType": "unfair_advantage",
      "function": "present_solution",
      "notes": "The slide uses a biological structural comparison to highlight the unique binding domain of the NXC-201 product.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/14",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-14",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 10,
          "beatId": "7f3ecbba-6032-4531-bb7e-529e9174ab66",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Desire",
          "beatSlug": "aida-desire",
          "evidence": "The competitive analysis, solution advantages, and clinical data create desire for the technology",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 15,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes comparative data charts for transduction efficiency and signaling, and flow cytometry data for anti-exhaustion.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/15",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-15",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 10,
          "beatId": "7f3ecbba-6032-4531-bb7e-529e9174ab66",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Desire",
          "beatSlug": "aida-desire",
          "evidence": "The competitive analysis, solution advantages, and clinical data create desire for the technology",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 16,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses a longitudinal timeline comparison to highlight the superior safety and efficacy profile of NXC-201.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/16",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-16",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 10,
          "beatId": "7f3ecbba-6032-4531-bb7e-529e9174ab66",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Desire",
          "beatSlug": "aida-desire",
          "evidence": "The competitive analysis, solution advantages, and clinical data create desire for the technology",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 17,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The chart illustrates the correlation between the peak of HBI0101 cells and the subsequent drop in dFLC, a marker for AL Amyloidosis.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/17",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-17",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 10,
          "beatId": "7f3ecbba-6032-4531-bb7e-529e9174ab66",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Desire",
          "beatSlug": "aida-desire",
          "evidence": "The competitive analysis, solution advantages, and clinical data create desire for the technology",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 18,
      "slideType": "problem_statement",
      "function": "frame_problem",
      "notes": "The slide uses a causal chain to link cellular pathology to systemic organ damage.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/18",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-18",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 19,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses a grouped bar chart format to highlight clinical superiority. Includes a disclaimer about cross-trial comparisons.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/19",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-19",
      "loopMatches": [
        {
          "to": 22,
          "from": 19,
          "name": "David Goliath",
          "slug": "16-david-goliath",
          "bestFor": "Startups, disruptive innovation, competitive displacement",
          "matchId": "4e0762bd-4e3f-4b14-9e84-63473b64f353",
          "evidence": "The deck compares NXC-201 to existing CAR-T therapies",
          "position": 1,
          "objective": "Position NXC-201 as a superior solution",
          "structure": "The Giant's Weakness -> Our Slingshot (Unique Edge) -> The Topple",
          "confidence": 0.7,
          "description": "Frame your initiative as the nimble underdog taking on a slow, bloated incumbent"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 20,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "The slide uses a table structure to contrast patient segments and includes a bar chart visualization for patient growth.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/20",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-20",
      "loopMatches": [
        {
          "to": 22,
          "from": 19,
          "name": "David Goliath",
          "slug": "16-david-goliath",
          "bestFor": "Startups, disruptive innovation, competitive displacement",
          "matchId": "4e0762bd-4e3f-4b14-9e84-63473b64f353",
          "evidence": "The deck compares NXC-201 to existing CAR-T therapies",
          "position": 1,
          "objective": "Position NXC-201 as a superior solution",
          "structure": "The Giant's Weakness -> Our Slingshot (Unique Edge) -> The Topple",
          "confidence": 0.7,
          "description": "Frame your initiative as the nimble underdog taking on a slow, bloated incumbent"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 21,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/21",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-21",
      "loopMatches": [
        {
          "to": 22,
          "from": 19,
          "name": "David Goliath",
          "slug": "16-david-goliath",
          "bestFor": "Startups, disruptive innovation, competitive displacement",
          "matchId": "4e0762bd-4e3f-4b14-9e84-63473b64f353",
          "evidence": "The deck compares NXC-201 to existing CAR-T therapies",
          "position": 1,
          "objective": "Position NXC-201 as a superior solution",
          "structure": "The Giant's Weakness -> Our Slingshot (Unique Edge) -> The Topple",
          "confidence": 0.7,
          "description": "Frame your initiative as the nimble underdog taking on a slow, bloated incumbent"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 22,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "Includes a footnote citing FDA approval precedents for similar single-arm studies.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/22",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-22",
      "loopMatches": [
        {
          "to": 22,
          "from": 19,
          "name": "David Goliath",
          "slug": "16-david-goliath",
          "bestFor": "Startups, disruptive innovation, competitive displacement",
          "matchId": "4e0762bd-4e3f-4b14-9e84-63473b64f353",
          "evidence": "The deck compares NXC-201 to existing CAR-T therapies",
          "position": 1,
          "objective": "Position NXC-201 as a superior solution",
          "structure": "The Giant's Weakness -> Our Slingshot (Unique Edge) -> The Topple",
          "confidence": 0.7,
          "description": "Frame your initiative as the nimble underdog taking on a slow, bloated incumbent"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 23,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "Uses a visual icon-grid to represent market expansion.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/23",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-23",
      "loopMatches": [
        {
          "to": 25,
          "from": 23,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "1265a475-93e6-4ebc-8b28-340faedfbff9",
          "evidence": "The deck mentions the potential market impact of delayed CAR-T adoption",
          "position": 2,
          "objective": "Highlight the need for NXC-201",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 24,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes detailed source citations in the footer; uses color-coded bars to represent different drug therapies.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/24",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-24",
      "loopMatches": [
        {
          "to": 25,
          "from": 23,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "1265a475-93e6-4ebc-8b28-340faedfbff9",
          "evidence": "The deck mentions the potential market impact of delayed CAR-T adoption",
          "position": 2,
          "objective": "Highlight the need for NXC-201",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 25,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "The slide uses a two-column layout to separate milestones by drug candidate.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/25",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-25",
      "loopMatches": [
        {
          "to": 25,
          "from": 23,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "1265a475-93e6-4ebc-8b28-340faedfbff9",
          "evidence": "The deck mentions the potential market impact of delayed CAR-T adoption",
          "position": 2,
          "objective": "Highlight the need for NXC-201",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 26,
      "slideType": "roadmap",
      "function": "show_traction",
      "notes": "The slide uses a standard pharmaceutical pipeline table format with clinical and preclinical segments.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/26",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-26",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 27,
      "slideType": "why_now",
      "function": "argue_timing",
      "notes": "Includes a comparison table of clinical outcomes (ORR/CR) between NXC-201 and competitors.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/27",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-27",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 28,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The slide uses a wave-like visual to represent market segments and their associated financial opportunities.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/28",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-28",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 29,
      "slideType": "transition",
      "function": "transition",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/29",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-29",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 30,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/30",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-30",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 31,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The chart uses a grouped bar structure to compare NXC-201 (green) against competitors (blue/red) across three categories: No BCMA, Yes BCMA, and Overall.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/31",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-31",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 32,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses a structured comparison table to highlight clinical advantages. It includes a disclaimer about cross-trial comparisons.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/32",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-32",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 33,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The slide uses a comparative structure to present data for two distinct indications side-by-side.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/33",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-33",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 34,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The chart demonstrates deepening clinical responses over time for NXC-201 therapy.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/34",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-34",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 35,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "The table displays clinical safety data for NXC-201, specifically focusing on Cytokine Release Syndrome and Immune cell associated Neurotoxicity.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/35",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-35",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 36,
      "slideType": "peer_benchmark",
      "function": "compare_peers",
      "notes": "The slide highlights specific safety metrics for a competitor's product, likely to contrast with the presenter's own product profile.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/36",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-36",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 37,
      "slideType": "appendix_methodology",
      "function": "plan_implementation",
      "notes": "The diagram illustrates a dose-escalation process leading to the RP2D.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/37",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-37",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 38,
      "slideType": "section_divider",
      "function": "transition",
      "notes": "The slide features a scientific illustration of cellular structures, likely representing the drug delivery mechanism.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/38",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-38",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 39,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes scientific diagrams of molecular pathways and bar/line charts showing efficacy data.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/39",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-39",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 40,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Slide presents three distinct preclinical data sets: survival in STS, tumor response in STS, and survival in KPC pancreatic cancer models.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/40",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-40",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 41,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes a process flow diagram illustrating the mechanism of action of iMX-110 in tumor microenvironments.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/41",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-41",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 42,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes both internal unpublished data and external reference data from Winograd et al. (2015).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/42",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-42",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
      "docSlug": "c241ac9edd2443452257949ce0a73d65",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 43,
      "slideType": "section_divider",
      "function": "transition",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/43",
      "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
      "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-43",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 61,
          "from": 18,
          "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
          "arcName": "AIDA",
          "arcSlug": "aida",
          "beatName": "Action",
          "beatSlug": "aida-action",
          "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    }
  ]
}